Role of tumor necrosis factor-α in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate

Circulation Journal

Volumn 77, Issue 5, 2013, Pages 1171-1179

  Liew, Reginald ^a,b   Khairunnisa, Katwadi ^a   Gu, Yacui ^a   Tee, Nicole ^a   Yin, New Oo ^a   Naylynn, Tin Maung ^a   Moe, Kyaw Thu ^a  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Atrial fibrosis; Immunohistochemistry; Transforming growth factor ; Tumor necrosis factor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CONNEXIN 40; CYTOKINE; GELATINASE A; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FIBROSIS; HEART ATRIUM FIBRILLATION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PILOT STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING;

ACTINS; ANIMALS; ARRHYTHMIAS, CARDIAC; ATRIAL FUNCTION; CONNEXIN 43; CONNEXINS; DOWN-REGULATION; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; HEART ATRIA; INJECTIONS, INTRAVENOUS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MYOFIBROBLASTS; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876768520     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1155     Document Type: Article

References (36)

1. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998; 274: R577-R595.
2. Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 2010; 127: 295-314.
3. Wu CK, Lee JK, Chiang FT, Yang CH, Huang SW, Hwang JJ, et al. Plasma levels of tumor necrosis factor-alpha and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase. Crit Care Med 2011; 39: 984-992.
4. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-711.
5. Jobe LJ, Melendez GC, Levick SP, Du Y, Brower GL, Janicki JS. TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. Am J Physiol Heart Circ Physiol 2009; 297: H1462-H1468.
6. Saba S, Janczewski AM, Baker LC, Shusterman V, Gursoy EC, Feldman AM, et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiacspecific overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart Circ Physiol 2005; 289: H1456-H1467.
7. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 1999; 27: 1309-1318.
8. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998; 97: 1375-1381.
9. Patten M, Kramer E, Bunemann J, Wenck C, Thoenes M, Wieland T, et al. Endotoxin and cytokines alter contractile protein expression in cardiac myocytes in vivo. Pflugers Arch 2001; 442: 920-927.
10. Everett TH, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 2007; 4: S24-S27.
11. Burstein B, Nattel S. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51: 802-809.
12. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010; 7: 438-444.
13. Haimerl F, Erhardt A, Sass G, Tiegs G. Down-regulation of the deubiquitinating enzyme ubiquitin-specific protease 2 contributes to tumor necrosis factor-alpha-induced hepatocyte survival. J Biol Chem 2009; 284: 495-504.
14. Moe KT, Yin NO, Naylynn TM, Khairunnisa K, Wutyi MA, Gu Y, et al. Nox2 and Nox4 mediate tumour necrosis factor-alpha-induced ventricular remodelling in mice. J Cell Mol Med 2011; 15: 2601-2613.
15. Pollick C, Hale SL, Kloner RA. Echocardiographic and cardiac Doppler assessment of mice. J Am Soc Echocardiogr 1995; 8: 602-610.
16. Lijnen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 2000; 71: 418-435.
17. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010; 106: 1675-1680.
18. Evans RA, Tian YC, Steadman R, Phillips AO. TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp Cell Res 2003; 282: 90-100.
19. Anne W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P, et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res 2005; 67: 655-666.
20. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: A current perspective. Cardiovasc Res 2002; 53: 822-830.
21. Kim SK, Park JH, Kim JY, Choi JI, Joung B, Lee MH, et al. High plasma concentrations of transforming growth factor-beta and tissue inhibitor of metalloproteinase-1: Potential non-invasive predictors for electroanatomical remodeling of atrium in patients with nonvalvular atrial fibrillation. Circ J 2011; 75: 557-564.
22. Choi EK, Chang PC, Lee YS, Lin SF, Zhu W, Maruyama M, et al. Triggered firing and atrial fibrillation in transgenic mice with selec tive atrial fibrosis induced by overexpression of TGF-beta1. Circ J 2012; 76: 1354-1362.
23. Parthenakis FI, Patrianakos AP, Skalidis EI, Diakakis GF, Zacharis EA, Chlouverakis G, et al. Atrial fibrillation is associated with increased neurohumoral activation and reduced exercise tolerance in patients with non-ischemic dilated cardiomyopathy. Int J Cardiol 2007; 118: 206-214.
24. Porter KE, Turner NA, O'Regan DJ, Ball SG. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: Inhibition by simvastatin. Cardiovasc Res 2004; 64: 507-515.
25. Burstein B, Comtois P, Michael G, Nishida K, Villeneuve L, Yeh YH, et al. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res 2009; 105: 1213-1222.
26. Berry MF, Woo YJ, Pirolli TJ, Bish LT, Moise MA, Burdick JW, et al. Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling. J Heart Lung Transplant 2004; 23: 1061-1068.
27. Gurantz D, Yndestad A, Halvorsen B, Lunde OV, Omens JH, Ueland T, et al. Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling. Cardiovasc Res 2005; 67: 106-115.
28. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001; 103: 1044-1047.
29. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594-1602.
30. Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 2005; 95: 17C-23C.
31. Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997; 25: 1813-1819.
32. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167: 1655-1663.
33. Lee SH, Chen YC, Chen YJ, Chang SL, Tai CT, Wongcharoen W, et al. Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci 2007; 80: 1806-1815.
34. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
35. Chaldoupi SM, Loh P, Hauer RN, de Bakker JM, van Rijen HV. The role of connexin40 in atrial fibrillation. Cardiovasc Res 2009; 84: 15-23.
36. Severs NJ, Bruce AF, Dupont E, Rothery S. Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res 2008; 80: 9-19.